Latest Convergence Pharmaceuticals Limited Stories
CAMBRIDGE, England, July 19, 2011 /PRNewswire/ -- Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines, today announces that the Phase II proof of concept study with CNV1014802 for treating pain associated with lumbosacral radiculopathy (LSR) has started. LSR is a common neuropathic pain condition caused by compression of the nerve roots in the lumbar region of the spine.
CAMBRIDGE, England, April 21, 2011 /PRNewswire/ -- - First-time-in-man Study Initiated Ahead of Schedule Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines, today announced that the first-time-in-man Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated and dosing has begun. The trial is a randomised, placebo...
- A person in a secondary role, specifically the second most important character (after the protagonist).